8-K: Clene Inc. Announces Positive Long-Term Results for CNM-Au8 in Multiple Sclerosis Trial

Clene Inc. reported significant and sustained improvements in vision and cognition in multiple sclerosis patients treated with CNM-Au8 over a 35-month period.

Summary

• Clene Inc. presented long-term clinical results from the VISIONARY-MS trial extension at the ACTRIMS Forum 2024.
• The study evaluated the effects of CNM-Au8 30mg on patients with stable relapsing multiple sclerosis (RMS).
• The long-term extension (LTE) followed 55 of 69 eligible participants for up to an additional 96 weeks after the initial double-blind period.
• Results showed significant improvement in vision, measured by low contrast letter acuity (LCLA), through 35 months from randomization with a p-value of less than 0.0001.
• Cognition, measured by the Symbol Digit Modality Test (SDMT), also showed significant improvement through 35 months with a p-value of less than 0.0001.
• The modified MS Functional Composite (mMSFC) scale, which includes vision, cognition, upper extremity function, and walking speed, also showed significant improvement with a p-value of 0.018.
• The treatment was well-tolerated, with no serious adverse events attributed to CNM-Au8.

Sentiment

Score: 8

Explanation: The document presents very positive clinical results with statistically significant improvements and good tolerability, suggesting a strong potential for the drug. However, the inherent risks of drug development and regulatory approval temper the overall sentiment.

Positives

• CNM-Au8 demonstrated significant and sustained improvements in vision, cognition, and overall neurological function in MS patients.
• The treatment was well-tolerated with a high compliance rate of 94%.
• The study showed clinically meaningful improvements in individual patients, with some experiencing gains of up to 38 letters in vision and 29 points in cognition.
• The results suggest a potential for CNM-Au8 to provide long-term benefits for patients with multiple sclerosis.

Negatives

• The study focused on a specific subset of MS patients (stable relapsing MS with chronic optic neuropathy) and may not be generalizable to all MS patients.
• The study was an open-label extension, which may introduce bias compared to a double-blind, placebo-controlled trial.

Risks

• The company's ability to obtain regulatory approval for CNM-Au8 is not guaranteed.
• The company's ability to achieve commercial success for CNM-Au8, if approved, is subject to market conditions and competition.
• The company has a limited operating history and may require additional funding to complete development and commercialization of its drug candidates.
• The company's future results may be materially different from those expressed or implied by forward-looking statements due to various risks and uncertainties.

Future Outlook

The company will continue to develop CNM-Au8 and other drug candidates, but the future results are subject to various risks and uncertainties.

Management Comments

• Clene Inc. presented full clinical results for CNM-Au8 from the VISIONARY-MS Trial long-term open label extension (LTE) in participants with stable relapsing multiple sclerosis (RMS) totaling nearly three years of follow-up at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in West Palm Beach, Florida.

Industry Context

The results are significant in the context of multiple sclerosis treatment, as they demonstrate the potential for a therapy to improve vision and cognition over a long period. This is particularly relevant given the limited treatment options for progressive forms of MS and the need for therapies that can address both physical and cognitive symptoms.

Comparison to Industry Standards

• The reported improvements in LCLA, SDMT, and mMSFC are clinically meaningful and compare favorably to other treatments for MS.
• The long-term nature of the study, with data collected over 35 months, provides valuable insights into the sustained efficacy of CNM-Au8.
• While direct comparisons to other specific MS drugs are difficult without head-to-head trials, the magnitude of improvement observed in this study suggests a potentially significant benefit for patients.
• Other companies such as Biogen, Novartis, and Roche have developed MS treatments, but the unique mechanism of action of CNM-Au8 targeting mitochondrial health could offer a different approach to managing the disease.

Stakeholder Impact

• Shareholders may react positively to the strong clinical results.
• Patients with MS may have increased hope for new treatment options.
• Employees may be motivated by the positive progress of the company's drug development program.
• The results may attract potential partners and investors.

Next Steps

• The company will likely continue to analyze the data and potentially move forward with further clinical trials and regulatory submissions.
• The company may also present these results at other scientific conferences and publications.

Key Dates

Keywords

CNM-Au8, Multiple Sclerosis, VISIONARY-MS, Clinical Trial, Neurodegenerative Diseases, Mitochondrial Health, LCLA, SDMT, mMSFC, ACTRIMS